Why Measure Unbound Fraction in a Microsomal Incubation?
A drug added to a microsomal incubation may distribute between the aqueous solution and microsomal membranes. Only part of the drug in the incubation is present as unbound drug in the aqueous phase at a given time. Measuring that fraction requires separating or otherwise estimating the unbound drug without changing the binding equilibrium so much that the measurement no longer represents the incubation.
This tutorial focuses on the measurement itself: what the fraction means, how to obtain it, and how to decide whether an assay result is credible. The measurement is specific to the drug and the conditions used. Microsomal protein concentration, drug concentration, pH, temperature, solvent content, and incubation composition can all affect binding. A reported value therefore needs those conditions to be interpretable.
The term “unbound” describes drug not associated with microsomal material under the stated assay conditions. It does not mean that the drug is unbound in plasma or in another biological matrix. Nor does a measured fraction, by itself, establish how much drug will be metabolized. The earlier material on scaling microsomal clearance establishes the broader IVIVE context; the measurement addressed here supplies an assay-specific binding quantity.
Equilibrium Dialysis
In equilibrium dialysis, a membrane separates two chambers. The membrane allows the small drug molecules to pass but retains microsomes. The donor chamber contains drug and microsomes; the receiver chamber contains buffer without microsomes. After the system reaches equilibrium, unbound drug concentrations are equal on both sides, provided that the membrane is permeable to the drug and the two chambers have compatible conditions. The receiver concentration then estimates the donor’s unbound concentration, while the donor’s total concentration is measured after accounting for drug associated with microsomes.
The donor concentration must be a total concentration: the sample is processed to release and measure drug whether it was free or microsome-associated. The receiver sample, by contrast, is normally measured directly as dissolved drug. Quantitative analytical recovery from both chambers matters. If drug adheres to the membrane or apparatus, degrades, or precipitates, the chamber concentrations may not give a reliable estimate.
Deriving the Calculation and Checking Mass Balance
Suppose equal donor and receiver volumes are used, and the receiver contains no binding material. At equilibrium, the receiver concentration is \(C_u\). If the donor total concentration is \(C_{\mathrm{tot}}\), the amount in the two fluid chambers is the sum of the amount in the donor and receiver. With equal chamber volumes \(V\), that fluid-phase amount is \(C_{\mathrm{tot}}V+C_uV\). The initial drug amount should be close to this sum if there is no loss to the apparatus or transformation of the drug. Independently, the fraction estimate follows directly from the definition:
The mass-balance check is not a substitute for the ratio. It is a diagnostic: it helps reveal missing drug, but does not show that the measured equilibrium was reached or that the device did not perturb the binding. For unequal volumes, calculate amounts using each chamber’s own volume; do not compare amounts as though the volumes were equal.
Worked Example: Estimating the Fraction by Equilibrium Dialysis
In a hypothetical assay, 0.200 mL of donor solution begins at 1.00 µmol/L and contains microsomes. The receiver contains 0.200 mL of buffer. After a validated dialysis interval, the measured donor total concentration is 0.700 µmol/L and the receiver concentration is 0.280 µmol/L. Assume the drug is stable, the receiver has no binding constituents, and the reported concentrations are analytically valid.
Starting amount. The initial drug amount in the donor is:
Fraction estimate. The receiver concentration estimates the unbound concentration, so:
The estimated unbound fraction is 0.400, or 40.0%, under these assay conditions.
Mass-balance check. The donor amount at the end is \(0.700\ \mathrm{\mu mol/L}\times0.000200\ \mathrm{L}=0.000140\ \mathrm{\mu mol}=140\ \mathrm{pmol}\). The receiver amount is \(0.280\ \mathrm{\mu mol/L}\times0.000200\ \mathrm{L}=0.0000560\ \mathrm{\mu mol}=56.0\ \mathrm{pmol}\). Thus, \(140+56.0=196\ \mathrm{pmol}\), and recovery in the two fluid chambers is \(196/200=0.980\), or 98.0%. This supports good overall recovery, though device-specific controls and evidence of equilibrium are still needed.
Controls for Recovery, Device Binding, and Stability
A plausible ratio is not enough to establish a sound measurement. Include controls that reveal whether drug has been lost or altered and whether the separation method itself affects the result. In a dialysis experiment, record the starting amount, measure both chambers, and, where practical, extract or rinse the membrane and apparatus to assess retained drug. Run a drug-only device control without microsomes: appreciable loss in this control points to nonspecific adsorption or another device-related problem. A buffer or matrix blank can identify analytical interference.
Recovery is commonly assessed as the measured drug amount in relevant chambers divided by the starting amount, with any measured apparatus-associated amount reported separately. A low recovery warns that the concentration ratio may be unreliable. A high recovery does not, by itself, prove that the drug was at equilibrium, that chamber concentrations were measured without bias, or that the drug did not bind to microsomes. Conversely, finding drug on a device does not justify automatically multiplying the fraction by a recovery correction: the loss can alter the distribution during the experiment, and the correction is not generally known from total recovery alone.
Check chemical stability under the actual dialysis time, temperature, and buffer conditions. If drug is transformed, disappearance from the chambers can be mistaken for binding-related loss. Use conditions that minimize transformation when the goal is to measure binding, and verify stability using an appropriate drug-only control. Confirm that the compound remains soluble at the chosen concentration; precipitation also produces apparent loss.
Worked Example: Interpreting Incomplete Recovery
In a hypothetical equal-volume dialysis experiment, the starting donor contains 200 pmol of drug in 0.200 mL. At the endpoint, donor total concentration is 0.600 µmol/L and receiver concentration is 0.200 µmol/L. A rinse of the dialysis device contains 30 pmol. A drug-only control without microsomes also shows substantial device-associated drug.
Apparent fraction. From the chamber concentrations:
Fluid-chamber recovery. The donor amount is \(0.600\ \mathrm{\mu mol/L}\times0.000200\ \mathrm{L}=120\ \mathrm{pmol}\). The receiver amount is \(0.200\ \mathrm{\mu mol/L}\times0.000200\ \mathrm{L}=40.0\ \mathrm{pmol}\). Recovery in the fluid chambers is \((120+40.0)/200=0.800\), or 80.0%.
Including the 30 pmol recovered in the device rinse gives \((120+40.0+30)/200=0.950\), or 95.0% overall measured recovery. The apparent fraction is not automatically invalid, but the appreciable device association and 80.0% recovery in the chambers are warnings. The drug-only control supports a device-binding explanation. Repeat or validate the measurement using a suitable low-binding device and assess whether the chamber ratio is stable; do not treat the 95.0% total recovery as a mathematical correction to the fraction.
Other Measurement Methods
Equilibrium dialysis is often useful because it allows drug to redistribute until the freely dissolved concentrations equilibrate across a membrane. It can, however, be slow and vulnerable to membrane adsorption, incomplete equilibration, and instability during the incubation. Alternative separation methods can be faster, but their results require method-specific checks.
| Method | Basic measurement | Important checks and limitations |
|---|---|---|
| Equilibrium dialysis | After equilibration, receiver concentration estimates free drug; donor sample gives total drug. | Confirm equilibration, drug stability, membrane permeability, and recovery. Device binding can reduce reliability. |
| Ultrafiltration | A filter retains microsomes while free drug passes into the filtrate; filtrate concentration estimates free drug. | Check nonspecific filter binding and recovery. Filtration can change volume and concentrate retained microsomes, potentially shifting binding equilibrium. |
| Ultracentrifugation | Microsomes are sedimented, and drug concentration in the separated aqueous supernatant estimates free drug. | Check complete separation, drug stability, and adsorption to tubes or the pellet. Incomplete sedimentation can contaminate the supernatant with microsomes. |
For ultrafiltration or ultracentrifugation, compare the measured free concentration with the total concentration in the original incubation, under conditions that preserve the relevant equilibrium. The fact that a method separates microsomes quickly does not ensure that the resulting free concentration equals the one present before separation. For example, filtering a large fraction of the sample can concentrate the retained microsomes and change the binding conditions. Use a short, validated procedure and assess whether the estimate depends on the volume processed.
Worked Example: Assessing an Ultrafiltration Result
In a hypothetical incubation, the total drug concentration before separation is 0.800 µmol/L. Ultrafiltration produces a filtrate concentration of 0.220 µmol/L. The starting amount is 160 pmol. The filtrate volume is 0.0400 mL, the recovered retentate contains 110 pmol, and a membrane rinse contains 25.0 pmol.
If the filtrate concentration represents the free concentration in the original incubation, the estimate is:
The filtrate amount is \(0.220\ \mathrm{\mu mol/L}\times0.0000400\ \mathrm{L}=0.00000880\ \mathrm{\mu mol}=8.80\ \mathrm{pmol}\). Overall measured recovery is \((8.80+110+25.0)/160=0.899\), or 89.9%. A membrane rinse containing 25.0 pmol is substantial relative to the 160 pmol starting amount, so nonspecific filter association is a concern. In addition, the filtrate represents only a small volume, but this alone does not rule out equilibrium shifts or separation artifacts. Treat 0.275 as provisional and compare it with a validated method or a filter-binding control before relying on it.
Choosing and Validating Assay Conditions
The binding measurement should represent the microsomal incubation of interest. Match the microsomal protein concentration, buffer composition, pH, temperature, solvent concentration, and drug concentration as closely as practical. Use the same microsomal preparation type and relevant matrix constituents. If a cofactor or other addition changes the assay environment, consider whether it could also change binding or drug stability; a measurement made in a different matrix may not represent the incubation.
Binding can depend on concentration. A single \(f_{u,\mathrm{mic}}\) value should therefore be reported with the drug concentration at which it was measured, rather than assumed to apply at every concentration. Where the intended assay spans a range, measure at more than one relevant concentration and check whether the ratio changes. Replicate measurements help reveal imprecision, but replication cannot repair a systematic problem such as incomplete equilibration or substantial device binding.
A practical validation sequence is to establish analytical performance and stability first, then test recovery and device binding, and finally demonstrate that the measured ratio is stable over a suitable equilibration interval. A time course can show whether receiver concentration has reached a plateau; a single endpoint cannot establish equilibrium by itself. Investigate unexpected differences between methods rather than averaging them automatically: the methods may have different artifacts or may have perturbed the binding equilibrium differently.
Specify the drug concentration and microsomal protein concentration, and reproduce relevant buffer, pH, temperature, and solvent conditions.
Use appropriate controls to identify transformation, precipitation, or analytical interference over the measurement interval.
Measure total drug in the donor and unbound drug in the receiver, or the corresponding quantities for the selected alternative method; check recovery and device association.
Use time-course or other suitable checks, assess method-specific artifacts, and report the conditions and controls alongside the estimated fraction.
Common Pitfalls and Interpretation
- Using the wrong denominator. Dividing receiver concentration by the initial donor concentration is not the defined ratio if the donor total concentration has changed during dialysis. Use the measured donor total concentration at the relevant endpoint.
- Equating recovery with validity. Good total recovery is reassuring but does not demonstrate equilibrium or correct separation. Poor recovery is a warning, not a license for an arbitrary numerical correction.
- Ignoring device binding. Drug on a membrane, filter, or tube can contribute to missing mass and can perturb the distribution. Include method-specific controls and investigate substantial association.
- Transferring a value across conditions. A fraction measured at one protein concentration, pH, or drug concentration is not automatically the fraction under different assay conditions.
- Assuming the method is artifact-free. Dialysis can be slow; filtration can concentrate retained microsomes; centrifugation can leave microsomes in the supernatant. Each method needs checks suited to its separation process.
The main alternatives differ in how they separate the microsomes from free drug, not in the definition of \(f_{u,\mathrm{mic}}\). Equilibrium dialysis offers an equilibrium-based estimate but requires time and good recovery. Ultrafiltration and ultracentrifugation may be faster, but can perturb the system or introduce separation-specific losses. The best method is the one validated for the compound and assay conditions, with a transparent recovery assessment.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions.
- In equal-volume equilibrium dialysis, the receiver concentration is 0.150 µmol/L and the donor total concentration is 0.600 µmol/L. What is \(f_{u,\mathrm{mic}}\)?
- Why is a drug-only device control useful in equilibrium dialysis?
- A filtration method reports a higher apparent unbound fraction when a larger sample volume is processed. What should be investigated?
- Give two reasons why high overall drug recovery does not, by itself, prove that a binding measurement is valid.
Solutions. (1) \(f_{u,\mathrm{mic}}=0.150/0.600=0.250\), or 25.0%. (2) It identifies drug association with the membrane or apparatus even without microsomes, revealing nonspecific device loss that could bias the measurement. (3) Investigate whether processing more volume concentrates retained microsomes or otherwise shifts the binding equilibrium; also check recovery and filter binding. (4) High recovery does not establish that equilibrium was reached, and it does not rule out biased separation, inaccurate chamber measurements, or a condition mismatch with the intended incubation.